The Diabetes Injection Pens Market is predicted to reach US$ ~15.65 billion by 2031 from US$ ~7.0 billion in 2020, and to grow at a CAGR of ~7.6% between the forecast period 2021 to 2031.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2021 to 2031. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2020. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Product Type (Insulin Pens and Pen Needles), Usage Type (Reusable Pens and Disposable Pens), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Stores)"
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Novo Nordisk A/S, B. Braun Melsungen AG, BD., Eli Lilly and Company, Gerresheimer AG, Sanofi., F. Hoffmann-La Roche Ltd., AstraZeneca, Biocon., Owen Mumford Ltd., among others.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2018 & 2019
2. Base Year - 2020
3. Forecasted Years - 2021 to 2031
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Diabetes Injection Pens Market - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Diabetes Injection Pens Market - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Diabetes Injection Pens Market - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Diabetes Injection Pens Market - ANALYSIS & FORECAST, BY REGION
North America Diabetes Injection Pens Market
1. North America Diabetes Injection Pens Market, by Country
1. US
2. Canada
1. North America Diabetes Injection Pens Market, by Product
2. North America Diabetes Injection Pens Market, by Type
3. North America Diabetes Injection Pens Market, by Gender
4. North America Diabetes Injection Pens Market, by Sales Channel
3. Europe Diabetes Injection Pens Market
1. Europe Diabetes Injection Pens Market, by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Diabetes Injection Pens Market, by Product
3. Europe Diabetes Injection Pens Market, by Type
4. Europe Diabetes Injection Pens Market, by Gender
5. Europe Diabetes Injection Pens Market, by Sales Channel
4. Asia Pacific Diabetes Injection Pens Market
1. Asia Pacific Diabetes Injection Pens Market, by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Diabetes Injection Pens Market, by product
3. Asia Pacific Diabetes Injection Pens Market, by Type
4. Asia Pacific Diabetes Injection Pens Market, by Gender
5. Asia Pacific Diabetes Injection Pens Market, by Sales Channel
5. Rest of the World Diabetes Injection Pens Market
1. Rest of the World Diabetes Injection Pens Market, by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Diabetes Injection Pens Market, by Product
3. Rest of the World Diabetes Injection Pens Market, by Type
4. Rest of the World Diabetes Injection Pens Market, by Gender
5. Rest of the World Diabetes Injection Pens Market, by Sales Channel
2. COMPANY PROFILES
Company 1, Company 30